Morote J - Search Results

1

External validation of the barcelona magnetic resonance imaging predictive model for detecting significant prostate cancer including men receiving 5-alpha reductase inhibitors.

Morote J, Borque-Fernando Á, Esteban LM, Picola N, Muñoz-Rodriguez J, Paesano N, Ruiz-Plazas X, Muñoz-Rivero MV, Celma A, Manuel GG, Miró B, Abascal JM, Servian P. Morote J, et al. World J Urol. 2024 Jul 10;42(1):393. doi: 10.1007/s00345-024-05092-0. World J Urol. 2024. PMID: 38985325 Free PMC article.

2

Increase of bone alkaline phosphatase after androgen deprivation therapy in patients with prostate cancer.

Morote J, M'Hammed YI, Martinez E, Esquena S, Lorente JA, Gelabert A. Morote J, et al. Urology. 2002 Feb;59(2):277-80. doi: 10.1016/s0090-4295(01)01518-7. Urology. 2002. PMID: 11834402

3

The percentage of free prostatic-specific antigen is also useful in men with normal digital rectal examination and serum prostatic-specific antigen between 10.1 and 20 ng/ml.

Morote J, Trilla E, Esquena S, Serrallach F, Abascal JM, Muñoz A, Id M'Hammed Y, de Torres IM. Morote J, et al. Eur Urol. 2002 Oct;42(4):333-7. doi: 10.1016/s0302-2838(02)00318-4. Eur Urol. 2002. PMID: 12361897

4

Nadir prostate-specific antigen best predicts the progression to androgen-independent prostate cancer.

Morote J, Trilla E, Esquena S, Abascal JM, Reventos J. Morote J, et al. Int J Cancer. 2004 Mar 1;108(6):877-81. doi: 10.1002/ijc.11639. Int J Cancer. 2004. PMID: 14712491

5

Gastric cancer in augmentation gastrocystoplasty.

Esquena Fernández S, Abascal JM, Tremps E, Morote J. Esquena Fernández S, et al. Among authors: morote j. Urol Int. 2005;74(4):368-70. doi: 10.1159/000084441. Urol Int. 2005. PMID: 15897707

6

Bone mineral density changes in patients with prostate cancer during the first 2 years of androgen suppression.

Morote J, Orsola A, Abascal JM, Planas J, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J. Morote J, et al. J Urol. 2006 May;175(5):1679-83; discussion 1683. doi: 10.1016/S0022-5347(05)00999-7. J Urol. 2006. PMID: 16600728

7

Failure to maintain a suppressed level of serum testosterone during long-acting depot luteinizing hormone-releasing hormone agonist therapy in patients with advanced prostate cancer.

Morote J, Esquena S, Abascal JM, Trilla E, Cecchini L, Raventós CX, Catalán R, Reventós J. Morote J, et al. Urol Int. 2006;77(2):135-8. doi: 10.1159/000093907. Urol Int. 2006. PMID: 16888418

8

Case report: retroperitoneal fibrosis simulating local relapse of sarcomatoid renal cell carcinoma.

Esquena S, Abascal JM, Trilla E, De Torres I, Morote J. Esquena S, et al. Among authors: morote j. Int Urol Nephrol. 2006;38(3-4):463-5. doi: 10.1007/s11255-006-6653-8. Int Urol Nephrol. 2006. PMID: 17146608

9

Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer.

Morote J, Morin JP, Orsola A, Abascal JM, Salvador C, Trilla E, Raventos CX, Cecchini L, Encabo G, Reventos J. Morote J, et al. Urology. 2007 Mar;69(3):500-4. doi: 10.1016/j.urology.2006.11.002. Urology. 2007. PMID: 17382153

10

Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.

Morote J, Orsola A, Planas J, Trilla E, Raventós CX, Cecchini L, Catalán R. Morote J, et al. J Urol. 2007 Oct;178(4 Pt 1):1290-5. doi: 10.1016/j.juro.2007.05.129. Epub 2007 Aug 14. J Urol. 2007. PMID: 17698136

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

302 results

Search Page

Filters